Specific targets in sarcoma and developmental therapeutics

JNCCN Journal of the National Comprehensive Cancer Network

Volumn 8, Issue 6, 2010, Pages 677-685

  Thomas, David M ^a   Wagner, Andrew J ^b  

^a PETER MACCALLUM CANCER CENTRE   (Australia)

^b DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

Drug targets; Mutation; Sarcoma; Therapy

Indexed keywords

AMG 479; ANTIBODY; BEVACIZUMAB; COLONY STIMULATING FACTOR 1; CP 751817; CYCLIN DEPENDENT KINASE 4; CYCLIN DEPENDENT KINASE INHIBITOR; DENOSUMAB; DOXORUBICIN; IMC A 12; MESENCHYMAL EPITHELIAL TRANSITION FACTOR; MESENCHYMAL EPITHELIAL TRANSITION FACTOR ANTIBODY; NILOTINIB; OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPROTEGERIN; P 1446 A 05; PROTEIN MDM2; PROTEIN P53; PROTEIN TYROSINE KINASE; PROTEIN TYROSINE KINASE INHIBITOR; R 1507; SCATTER FACTOR ANTIBODY; SCH 717454; SOMATOMEDIN C; SOMATOMEDIN C RECEPTOR; SUNITINIB; TEMOZOLOMIDE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VASCULOTROPIN; VASCULOTROPIN RECEPTOR; ANTINEOPLASTIC AGENT; ONCOPROTEIN; TUMOR MARKER; TUMOR PROTEIN;

CLINICAL TRIAL; CONNECTIVE TISSUE TUMOR; EWING SARCOMA; GIANT CELL TUMOR; HEMANGIOPERICYTOMA; HUMAN; ONCOGENE; PIGMENTED VILLONODULAR SYNOVITIS; REVIEW; SARCOMA; SOLITARY FIBROUS TUMOR; TENOSYNOVIAL GIANT CELL TUMOR; TUMOR CLASSIFICATION; ARTICLE; DRUG ANTAGONISM; METABOLISM; PATHOLOGY; PERSONALIZED MEDICINE;

ANTINEOPLASTIC AGENTS; HUMANS; INDIVIDUALIZED MEDICINE; NEOPLASM PROTEINS; ONCOGENE PROTEINS, FUSION; SARCOMA; TUMOR MARKERS, BIOLOGICAL;

EID: 77954153214     PISSN: 15401405     EISSN: 15401413     Source Type: Journal    
DOI: 10.6004/jnccn.2010.0050     Document Type: Review

References (68)

1. Demetri GD, von Mehren M, Blanke CD, et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med 2002;347:472-480.
2. McArthur GA, Demetri GD, van Oosterom A, et al. Molecular and clinical analysis of locally advanced dermatofibrosarcoma protuberans treated with imatinib: Imatinib Target Exploration Consortium Study B2225. J Clin Oncol 2005;23:866-673.
3. Maki RG, Awan RA, Dixon RH, et al. Differential sensitivity to imatinib of 2 patients with metastatic sarcoma arising from dermatofibrosarcoma protuberans. Int J Cancer 2002;100:623-626.
4. Rubin BP, Schuetze SM, Eary JF, et al. Molecular targeting of platelet-derived growth factor B by imatinib mesylate in a patient with metastatic dermatofibrosarcoma protuberans. J Clin Oncol 2002;20:3586-3591.
5. Sims NA, Gooi JH. Bone remodeling: multiple cellular interactions required for coupling of bone formation and resorption. Semin Cell Dev Biol 2008;19:444-451.
6. Dougall WC, Glaccum M, Charrier K, et al. RANK is essential for osteoclast and lymph node development. Genes Dev 1999;13:2412-2424.
7. Lacey DL, Timms E, Tan HL, et al. Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell 1998;93:165-176.
8. Simonet WS, Lacey DL, Dunstan CR, et al. Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell 1997;89:309-319.
9. Anderson DM, Maraskovsky E, Billingsley WL, et al. A homologue of the TNF receptor and its ligand enhance T-cell growth and dendritic-cell function. Nature 1997;390:175-179.
10. Kong YY, Yoshida H, Sarosi I, et al. OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis. Nature 1999;397:315-323.
11. Takahashi N, Udagawa N, Suda T. A new member of tumor necrosis factor ligand family, ODF/OPGL/TRANCE/RANKL, regulates osteoclast differentiation and function. Biochem Biophys Res Commun 1999;256:449-455. (Pubitemid 29301126)
12. Garsed DW, Holloway AJ, Thomas DM. Cancer-associated neochromosomes: a novel mechanism of oncogenesis. Bioessays 2009;31:1191-1200.
13. Morgan T, Atkins GJ, Trivett MK, et al. Molecular profiling of giant cell tumor of bone and the osteoclastic localization of ligand for receptor activator of nuclear factor kappaB. Am J Pathol 2005;167:117-128.
14. Atkins GJ, Haynes DR, Graves SE, et al. Expression of osteoclast differentiation signals by stromal elements of giant cell tumors. J Bone Miner Res 2000;15:640-649.
15. Fletcher CD, Unni KK, Merlens F, eds. World Health Organization classification of tumours: pathology and genetics of tumours of soft tissue and bone. Lyon, France: IARC Press; 2002.
16. Thomas DM, Skubitz KM. Giant cell tumour of bone. Curr Opin Oncol 2009;21:338-344.
17. Miller PD. Denosumab: anti-RANKL antibody. Curr Osteoporos Rep 2009;7:18-22.
18. Thomas D, Henshaw R, Skubitz K, et al. Denosumab in patients with giant-cell tumour of bone: an open-label, phase 2 study. Lancet Oncol 2010;11:275-280.
19. West RB, Rubin BP, Miller MA, et al. A landscape effect in tenosynovial giant-cell tumor from activation of CSF1 expression by a translocation in a minority of tumor cells. Proc Natl Acad Sci USA 2006;103:690-695.
20. Blay JY, El Sayadi H, Thiesse P, et al. Complete response to imatinib in relapsing pigmented villonodular synovitis/tenosynovial giant cell tumor (PVNS/TGCT). Ann Oncol 2008;19:821-822.
21. Toledo F, Wahl GM. Regulating the p53 pathway: in vitro hypotheses, in vivo Veritas. Nat Rev Cancer 2006;6:909-923.
22. Fulci G, Labuhn M, Maier D, et al. p53 gene mutation and ink4a-arf deletion appear to be two mutually exclusive events in human glioblastoma. Oncogene 2000;19:3816-3822.
23. Montes de Oca Luna R, Wagner DS, Lozano G. Rescue of early embryonic lethality in mdm2-deficient mice by deletion of p53. Nature 1995;378:203-206.
24. Momand J, Jung D, Wilczynski S, Niland J. The MDM2 gene amplification database. Nucleic Acids Res 1998;26:3453-3459.
25. Vassilev LT, Vu BT, Graves B, et al. In vivo activation of the p53 pathway by small-molecule antagonists of MDM2. Science 2004;303:844-848.
26. Liu W, He L, Ramirez J, Ratain MJ. Interactions between MDM2 and TP53 genetic alterations, and their impact on response to MDM2 inhibitors and other chemotherapeutic drugs in cancer cells. Clin Cancer Res 2009;15:7602-7607.
27. Burkhart DL, Sage J. Cellular mechanisms of tumour suppression by the retinoblastoma gene. Nat Rev Cancer 2008;8:671-682.
28. Malumbres M, Barbacid M. Cell cycle, CDKs and cancer: a changing paradigm. Nat Rev Cancer 2009;9:153-166.
29. Santamaria D, Barriere C, Cerqueira A, et al. Cdk1 is sufficient to drive the mammalian cell cycle. Nature 2007;448:811-815.
30. Shapiro GI. Cyclin-dependent kinase pathways as targets for cancer treatment. J Clin Oncol 2006;24:1770-1783. (Pubitemid 46628473)
31. Cheok CF, Dey A, Lane DP. Cyclin-dependent kinase inhibitors sensitize tumor cells to nutlin-induced apoptosis: a potent drug combination. Mol Cancer Res 2007;5:1133-1145. (Pubitemid 350137109)
32. DuBois S, Demetri G. Markers of angiogenesis and clinical features in patients with sarcoma. Cancer 2007;109:813-819. (Pubitemid 46333523)
33. D'Adamo DR, Anderson SE, Albritton K, et al. Phase II study of doxorubicin and bevacizumab for patients with metastatic soft-tissue sarcomas. J Clin Oncol 2005;23:7135-7142.
34. George S, Merriam P, Maki RG, et al. Multicenter phase II trial of sunitinib in the treatment of nongastrointestinal stromal tumor sarcomas. J Clin Oncol 2009;27:3154-3160.
35. Park MS, Patel SR, Ludwig JA, et al. Combination therapy with temozolomide and bevacizumab in the treatment of hemangiopericytoma/malignant solitary fibrous tumor [abstract]. J Clin Oncol 2008;26(Suppl 1):Abstract 10512.
36. Itakura E, Yamamoto J, Oda Y, Tsuneyoshi M. Detection and characterization of vascular endothelial growth factors and their receptors in a series of angiosarcomas. J Surg Oncol 2008;97:74-81.
37. Koontz BF, Miles EF, Rubio MA, et al. Preoperative radiotherapy and bevacizumab for angiosarcoma of the head and neck: two case studies. Head Neck 2008;30:262-266.
38. Agulnik M, Okuno SH, von Mehren M, et al. Bevacizumab for the treatment of angiosarcoma: an open-label multicenter phase II study [abstract]. Presented at the Connective Tissue Oncology Society Annual Meeting; November 5-7, 2009; Miami, Florida. Abstract 39250.
39. Antonescu CR, Yoshida A, Guo T, et al. KDR activating mutations in human angiosarcomas are sensitive to specific kinase inhibitors. Cancer Res 2009;69:7175-7179.
40. Stacchiotti S, Tamborini E, Marrari A, et al. Response to sunitinib malate in advanced alveolar soft part sarcoma. Clin Cancer Res 2009;15:1096-1104.
41. Gardner K, Judson I, Leahy M, et al. Activity of cediranib, a highly potent and selective VEGF signaling inhibitor, in alveolar soft part sarcoma [abstract]. J Clin Oncol 2009;27(Suppl 1):Abstract 10523.
42. Comoglio PM, Giordano S, Trusolino L. Drug development of MET inhibitors: targeting oncogene addiction and expedience. Nat Rev Drug Discov 2008;7:504-516.
43. Coltella N, Manara MC, Cerisano V, et al. Role of the MET/HGF receptor in proliferation and invasive behavior of osteosarcoma. FASEB J 2003;17:1162-1164.
44. Davis IJ, McFadden AW, Zhang Y, et al. Identification of the receptor tyrosine kinase c-Met and its ligand, hepatocyte growth factor, as therapeutic targets in clear cell sarcoma. Cancer Res 2010;70:639-645.
45. Diomedi-Camassei F, McDowell HP, De Ioris MA, et al. Clinical significance of CXC chemokine receptor-4 and c-Met in childhood rhabdomyosarcoma. Clin Cancer Res 2008;14:4119-4127.
46. Ginsberg JP, Davis RJ, Bennicelli JL, et al. Up-regulation of MET but not neural cell adhesion molecule expression by the PAX3-FKHR fusion protein in alveolar rhabdomyosarcoma. Cancer Res 1998;58:3542-3546.
47. Jun HJ, Lee J, Lim DH, et al. Expression of MET in alveolar soft part sarcoma. Med Oncol 2010;27:459-465.
48. Kikuchi K, Tsuchiya K, Otabe O, et al. Effects of PAX3-FKHR on malignant phenotypes in alveolar rhabdomyosarcoma. Biochem Biophys Res Commun 2008;365:568-574.
49. Lazar AJ, Lahat G, Myers SE, et al. Validation of potential therapeutic targets in alveolar soft part sarcoma: an immunohistochemical study utilizing tissue microarray. Histopathology 2009;55:750-755.
50. Patane S, Avnet S, Coltella N, et al. MET overexpression turns human primary osteoblasts into osteosarcomas. Cancer Res 2006;66:4750-4757.
51. Rees H, Williamson D, Papanastasiou A, et al. The MET receptor tyrosine kinase contributes to invasive tumour growth in rhabdomyosarcomas. Growth Factors 2006;24:197-208.
52. Stockwin L, Vistica DT, Kenney S, et al. Gene expression profiling of alveolar soft-part sarcoma (ASPS). BMC Cancer 2009;9:22.
53. Taulli R, Scuoppo C, Bersani F, et al. Validation of Met as a therapeutic target in alveolar and embryonal rhabdomyosarcoma. Cancer Res 2006;66:4742-4749.
54. Tsuda M, Davis IJ, Argani P, et al. TFE3 fusions activate MET signaling by transcriptional up-regulation, defining another class of tumors as candidates for therapeutic MET inhibition. Cancer Res 2007;67:919-929.
55. Relaix F, Polimeni M, Rocancourt D, et al. The transcriptional activator PAX3-FKHR rescues the defects of Pax3 mutant mice but induces a myogenic gain-of-function phenotype with ligand-independent activation of Met signaling in vivo. Genes Dev 2003;17:2950-2965.
56. Li Y, Chang Q, Rubin BP, et al. Insulin receptor activation in solitary fibrous tumours. J Pathol 2007;211:550-554.
57. Rikhof B, van Doorn J, Suurmeijer AJ, et al. Insulin-like growth factors and insulin-like growth factor-binding proteins in relation to disease status and incidence of hypoglycaemia in patients with a gastrointestinal stromal tumour. Ann Oncol 2009;20:1582-1588.
58. Tolcher AW, Sarantopoulos J, Patnaik A, et al. Phase I, pharmacokinetic, and pharmacodynamic study of AMG 479, a fully human monoclonal antibody to insulin-like growth factor receptor 1. J Clin Oncol 2009;27:5800-5807.
59. Tarn C, Rink L, Merkel E, et al. Insulin-like growth factor 1 receptor is a potential therapeutic target for gastrointestinal stromal tumors. Proc Natl Acad Sci U S A 2008;105:8387-8392.
60. Sabatini DM. mTOR and cancer: insights into a complex relationship. Nat Rev Cancer 2006;6:729-734.
61. Wan X, Helman LJ. The biology behind mTOR inhibition in sarcoma. Oncologist 2007;12:1007-1018.
62. Okuno SH, Mahoney MR, Bailey HH, et al. A multicenter phase 2 consortium (P2C) study of the mTOR inhibitor CCI-779 in advanced soft tissue sarcomas (STS) [abstract]. Proc Am Soc Clin Oncol 2006;24(Suppl 1):Abstract 9504.
63. Mita MM, Mita AC, Chu QS, et al. Phase I trial of the novel mammalian target of rapamycin inhibitor deforolimus (AP23573; MK-8669) administered intravenously daily for 5 days every 2 weeks to patients with advanced malignancies. J Clin Oncol 2008;26:361-367.
64. Chawla SP, Tolcher AW, Staddon AP, et al. Updated results of a phase II trial of AP23573, a novel mTOR inhibitor, in patients (pts) with advanced soft tissue or bone sarcomas [abstract]. Proc Am Soc Clin Oncol 2006;24(Suppl 1):Abstract 9505.
65. Iwenofu OH, Lackman RD, Staddon AP, et al. Phospho-S6 ribosomal protein: a potential new predictive sarcoma marker for targeted mTOR therapy. Mod Pathol 2007;21:231-237.
66. Wagner AJ, Malinowska-Kolodziej I, Morgan JA, et al. Clinical activity of mTOR inhibition with sirolimus in malignant perivascular epithelioid cell tumors: targeting the pathogenic activation of mTORC1 in tumors. J Clin Oncol 2010;28:835-840.
67. O'Reilly KE, Rojo F, She QB, et al. mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt. Cancer Res 2006;66:1500-1508.
68. Sun SY, Rosenberg LM, Wang X, et al. Activation of Akt and eIF4E survival pathways by rapamycin-mediated mammalian target of rapamycin inhibition. Cancer Res 2005;65:7052-7058.